School of Pharmaceutical Sciences of Taizhou University held on the afternoon of May 30th the 20th and 21st sessions of the “Hongyao Forum,” featuring academic lectures by Professor Wang Jianxin and Professor Shao Liming from the School of Pharmacy at Fudan University. Professor Jiang Xinguo, former Director of the Department of Pharmaceutics at Fudan University’s School of Pharmacy and Chief Scientist of the National 973 Program, attended the event. Also present were Hu Jinfeng, Dean of the School of Pharmaceutical Sciences, Li Na, Vice Dean, along with faculty representatives, graduate, and undergraduate students. The forum was hosted by Zhou Lisha, Vice Dean of the School of Pharmaceutical Sciences.
Hongyao Forum
Professor Wang Jianxin delivered a lecture titled “Generic Drugs vs. Original Drugs: The Trade-off Between Cost and Quality,” directly addressing the current widespread societal concerns regarding the differences in quality and efficacy between domestic generic drugs and imported original drugs. In his presentation, Wang provided an in-depth analysis of the core issue of how to scientifically evaluate the consistency between the two, systematically explained key factors that could lead to differences in efficacy, and discussed directions for industry improvement.
Importantly, from a professional perspective, Professor Wang offered valuable guidance to the public on how to rationally choose medications. His insights sparked strong resonance and deep reflection among the teachers and students present.
Professor Wang Jianxin delivering his report
Professor Shao Liming, with his lecture “Artificial Intelligence and Biopharmaceutical Innovation,” comprehensively showcased the increasingly widespread and in-depth application scenarios of artificial intelligence technology in the biopharmaceutical R&D sector, responding to the industry’s keen anticipation for the integrated development of “Biopharma + AI.” In his report, Professor Shao focused on the key proposition of how to accelerate the high-quality development of AI-driven biopharmaceutical innovation.
He joined the teachers and students in envisioning the grand blueprint of AI technology reshaping the drug R&D process, enhancing innovation efficiency, and opening up new therapeutic strategies, charting a promising future innovation path for all attendees.
Professor Shao Liming delivering his report
Dean Hu Jinfeng commented on the reports delivered by Professors Wang Jianxin and Shao Liming, expressing heartfelt thanks for their consistent strong support and assistance to the school’s development.
These academic lectures not only broadened the academic horizons of the participating teachers and students but also deepened their understanding and awareness of related research fields, highlighting the mission and responsibility of pharmaceutical professionals.
Expert Profiles:
Wang Jianxin: CPC Party Committee Secretary, Professor, and Ph.D. Supervisor at the School of Pharmacy, Fudan University. He also serves as Deputy Director of the National Key Laboratory of High-end Pharmaceutical Formulations for Overcoming Delivery Barriers, Director of the Institute of Pharmaceuticals, Fudan University Institute of Integrative Medicine, Director of the Joint Research Center for Complex Drug Formulations, and Head of the Shanghai Model Worker Innovation Studio for Novel Drug Formulations.
His main research focuses on the construction of novel drug delivery systems and the research and development of new pharmaceutical preparations and formulations. He has led over 30 national and provincial-level research projects, including the National Major New Drug Development Program and National Natural Science Foundation of China projects.
He has published over 220 academic papers in domestic and international journals such as Science Advances, ACS Nano, Nano-Micro Letters, and Journal of Controlled Release, including over 120 SCI papers. He has edited 4 planned textbooks or monographs including “Pharmaceutics” and “Biopharmaceutics and Pharmacokinetics,” and co-edited 6 textbooks or monographs.
He is responsible for the Shanghai High-Quality Course “Pharmacokinetics.” He has completed over 30 enterprise collaborative projects, obtained 16 new drug certificates or clinical trial approvals, and been granted over 20 invention patents.
He also serves as a member of the National Medical Products Administration Drug Registration Review Expert Advisory Committee, an expert for the National Assessment Committee for the Protection of Traditional Chinese Medicine Varieties, Vice Chairman of the Pharmaceutics Professional Committee of the Chinese Pharmaceutical Association, Vice President and Secretary-General of the Specialty Committee of Novel Delivery Systems for Traditional Chinese Medicine of the World Federation of Chinese Medicine Societies, Vice President of the Transdermal Therapy Branch of the Chinese Ethnic Medicine Association, member of the Industrial Pharmaceutics Professional Committee of the Chinese Pharmaceutical Association, member of the Nano Medicine and Engineering Branch of the Chinese Society of Biomedical Engineering, member of the Traditional Chinese Medicine Committee of the Chinese Association for National Unity and Progress, Vice Chairman of the Pharmaceutics Specialty Committee of the Shanghai Pharmaceutical Association, and Vice Chairman of the Traditional Chinese Medicine Branch of the Shanghai Association of Chinese Medicine.
He has received honors such as Shanghai Model Worker, Shanghai New Long March Pathbreaker, Shanghai Outstanding Technical Leader, and the Chinese Pharmaceutical Association - CSPC Youth Award in Pharmaceutics.
Shao Liming: Distinguished Professor of Fudan University, currently working in the Department of Medicinal Chemistry at the School of Pharmacy, Fudan University; Director of the Shanghai Center for Co-innovation in Drug Research and Development; Director of the Fudan University Center for Strategic Research on Healthcare and Pharmaceutical Industry Development; and PI at the Fudan University Institute of Brain Science and the State Key Laboratory of Medical Neurobiology.
He graduated with a bachelor’s degree from the Department of Chemistry, Fudan University, earned a Ph.D. in Engineering from the University of Tokyo, Japan, and completed postdoctoral research at Harvard University, USA.
With nearly 30 years of experience in drug research and development for various central nervous system drugs in pharmaceutical companies and research institutions, he has seen multiple drug candidates progress to various stages of clinical trials (Phase I, II, III, and NDA), accumulating extensive experience in drug R&D and process management.
He also promoted the establishment of the Fudan University Center for Strategic Research on Healthcare and Pharmaceutical Industry Development (a think tank), dedicated to research on the development strategies, policies, and innovation ecosystem of the biopharmaceutical industry.
